- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Fremont, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Fremont, California • Manhattan Beach, California • San Diego, California + 13 more